Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasms × Patient Reported Outcome Measures × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Preleukemia 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Precancerous Conditions 2 Neoplasms by Histologic Type 2 Neoplasms 2 Myelodysplastic Syndromes 2 Lymphoproliferative Disorders 2 Lymphoma 2 Lymphatic Diseases 2 Leukemia, Myeloid, Acute 2 Leukemia, Myeloid 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia, Lymphoid 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leukemia, Biphenotypic, Acute 2 Leukemia, B-Cell 2 Leukemia 2 Immunoproliferative Disorders 2 Immune System Diseases 2 Hematologic Diseases 2 Bone Marrow Diseases 2 Rectal Neoplasms 1 Primary Myelofibrosis 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Myeloproliferative Disorders 1 Leukemia, Prolymphocytic 1 Leukemia, Myelomonocytic, Chronic 1 Fatigue 1 Breast Neoplasms 1

Interventions

Trastuzumab 250 Cyclophosphamide 211 Paclitaxel 208 Docetaxel 201 Capecitabine 156 Letrozole 136 Carboplatin 131 Doxorubicin 121 Fulvestrant 120 Bevacizumab 102 Tamoxifen 85 Anastrozole 85 Vinorelbine 79 exemestane 75 Epirubicin 75 Gemcitabine 72 Lapatinib 70 pertuzumab 68 Radiotherapy 62 Albumin-Bound Paclitaxel 61 pembrolizumab 58 eribulin 50 palbociclib 49 Cisplatin 47 130-nm albumin-bound paclitaxel 45 Everolimus 41 Neoadjuvant Therapy 37 Goserelin 36 Taxes 35 pyrotinib 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05932667 2023-12-21

DEMETER

Institut Curie

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡